Development Pipeline

Janux’s initial development programs are designed to selectively activate T cells. The company leverages its proprietary tumor activated T cell engager (TRACTr) and its tumor activated immunomodulator (TRACIr) platforms to develop bispecific molecules that once activated are precision engineered to bind to specific tumor antigens and to T cells, thereby focusing T cells to attack the cancer while limiting toxicity elsewhere in the body. The company leverages its proprietary adaptive immune response modulator (ARM) platform to develop redesigned bispecific TCEs to improve efficacy and durability of response, coupled with a large safety window, for potential use in autoimmune diseases.